Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

Pillow, Thomas H., Adhikari, Pragya, Blake, Robert A., Chen, Jinhua, Del Rosario, Geoffrey, Deshmukh, Gauri, Figueroa, Isabel, Gascoigne, Karen E. +24 more·2020·ChemMedChem
DOI 10.1002/cmdc.201900497

Cited by (219)

Items 101–200 of 219

  1. Advancing Design Strategy of PROTACs for Cancer Therapy
    Hang Luo, Yuan Tian, Razack Abdullah, Bao‐Ting Zhang, Yuan Ma, Ge Zhang · 2025 · MedComm
  2. G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions
    Peyton C. High, Kendra S. Carmon · 2023 · Cancer Letters
  3. Modular Development of Enzyme-Activatable Proteolysis Targeting Chimeras for Selective Protein Degradation and Cancer Targeting
    Yanchi Chen, Lina Zhang, Lincheng Fang, Chengjie Chen, Dong Zhang, Tao Peng · 2024 · JACS Au
  4. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
    T. N. Rekha, Dongyun Shin · 2023 · International Journal of Molecular Sciences
  5. Precision targeting in oncology: The future of conjugated drugs
    Jiahe Li, Lei Liu, Xihe Zhao · 2024 · Biomedicine & Pharmacotherapy
  6. Ternary Complex‐Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo‐PROTACs
    Claudia J. Diehl, Alessandra Salerno, Alessio Ciulli · 2024 · Angewandte Chemie International Edition
  7. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
    Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Bowen Li, Mei Yang, Edouard Collins Nice, Huili Zhu, Canhua Huang · 2023 · European Journal of Medicinal Chemistry
  8. Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
    Mariana Ribeiro Monteiro, Natalia Nunes, Aumilto Junior, Â. Fêde, Gustavo de Oliveira Bretas, Cristiano de Pádua Souza, Max S. Mano, Jessé Lopes da Silva · 2024 · Breast Cancer Targets and Therapy
  9. Development of Ligands and Degraders Targeting MAGE-A3
    Ke Li, Mackenzie W. Krone, Arseniy Butrin, Michael J. Bond, Brian M. Linhares, Craig M. Crews · 2024 · Journal of the American Chemical Society
  10. Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton’s Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody–Drug Conjugates
    Alan Zhang, Katherine Seiss, Laurent Laborde, Sebastian Palacio-Ramirez, Daniel Alexander Guthy, Mylene Lanter, Julien Lorber, Anna Vulpetti, Luca Arista, Thomas Zoller et al. · 2024 · Bioconjugate Chemistry
  11. Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody–Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models
    Hiroyuki Kogai, Shuntaro Tsukamoto, Minaho Koga, Masayuki Miyano, Tsuyoshi Akagi, Atsumi Yamaguchi, Kiyoshi L. Mori, Kunihito Gotoh, Youya Nakazawa · 2025 · Molecular Cancer Therapeutics
  12. Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
    Qiuzhi Zhou, Weixia Wang, Chunchu Deng · 2025 · Molecular Neurobiology
  13. Targeted protein degradation technologies: Emerging mechanisms and nano-based innovations
    Mingge Hou, Runze Zhao, Shenghui Wang, Bing Jiang, Xiyun Yan · 2025 · Nano Research
  14. The emergence of AntibodyPlus: the future trend of antibody-based therapeutics
    Yong Zhu, Shawn Shouye Wang, Zhaohui Sunny Zhou, Mitchell Ho · 2022 · Antibody Therapeutics
  15. Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines
    Ziqin Yan, Xilin Lyu, Dongze Lin, Gaoxing Wu, Yang Gong, Xuelian Ren, Jian Xiao, Jianfeng Lou, He Huang, Yi Chen et al. · 2023 · European Journal of Medicinal Chemistry
  16. Quantitative Measurement of Rate of Targeted Protein Degradation
    Thomas L. Lynch, Violeta L. Marin, Ryan A. McClure, Colin J. Phipps, Judith A. Ronau, Milad Rouhimoghadam, Ashley M. Adams, Soumya Kandi, Malerie L. Wolke, Andrea G. Shergalis et al. · 2024 · ACS Chemical Biology
  17. Intracellular Delivery of Native Proteins by BioReversible Arginine Modification (BioRAM) on Amino Groups
    Jonathan Franke, Jan Vincent V. Arafiles, Christian Leis, Christian P. R. Hackenberger · 2025 · Angewandte Chemie International Edition
  18. Antibody–Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies
    Hussein Sabit, Salma Abbas, Moataz T. El-Safoury, Engy M. Madkour, Sahar Mahmoud, Shaimaa E. Abdel-Ghany, Yasser Albrahim, Ibtesam S. Al-Dhuayan, Sanaa Rashwan, Ahmed H. K. El-Hashash et al. · 2025 · Biomedicines
  19. Precise Modulation of Protein Degradation by Smart PROTACs
    Junfei Cheng, Guoqiang Dong, Wei Wang, Chunquan Sheng · 2024 · ChemBioChem
  20. Recent advances in medicinal chemistry strategies for the development of METTL3 inhibitors
    Gengwu Li, Wei Chen, Dan Liu, Shibing Tang · 2025 · European Journal of Medicinal Chemistry
  21. PROTAC Compatibilities, Degrading Cell‐Surface Receptors, and the Sticky Problem of Finding a Molecular Glue
    Conghe Tian, Kevin Burgess · 2020 · ChemMedChem
  22. The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma
    Di Wu, Hongli Yin, Chun Yang, Zi-Mu Zhang, Fang Fang, Jianwei Wang, Xiaolu Li, Yi Xie, Xiaohan Hu, Ran Zhuo et al. · 2024 · BMC Cancer
  23. Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy
    Lixia Chen, Xinqiang Wan, Xiangxiang Shan, Wenzhang Zha, Rengen Fan · 2022 · Molecular Diagnosis & Therapy
  24. Native Mass Spectrometry: Insights and Opportunities for Targeted Protein Degradation
    Louise M. Sternicki, Sally‐Ann Poulsen · 2023 · Analytical Chemistry
  25. Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed
    Karim Kanbar, Roy El Darzi, Diana E. Jaalouk · 2024 · Frontiers in Genetics
  26. Hypoxia-sensitive macrocycle inclusion complexes for targeted protein degradation
    Jiachan Lin, Wenyan Wang, An‐Kang Ying, Zirui Chen, Dan Zhang, Chendi Ding, Xiaowei Zeng, Dong‐Sheng Guo, Hongzhong Chen · 2025 · Journal of Controlled Release
  27. FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation
    Anil Kumar, Saghir Ali, Qiang Shen, Jia Zhou · 2026 · Journal of Medicinal Chemistry
  28. Antibody-drug conjugates (ADCs): “Smart Missiles” targeting cancer therapy
    Xiaoyang Yao, Yingying Lu, Shuo Shi, Yu Wang · 2025 · Colloids and Surfaces B Biointerfaces
  29. Cascade-responsive nano-PROTACs for tumor-specific ALK protein degradation and enhanced cancer therapy
    Yanping Zhao, Junhui Sui, Jian Chang, Jianxiong Liu, Xiaoqian Wang, Hongjun Wang, Wei Chen, Binlong Chen, Yiguang Wang · 2025 · Nano Today
  30. Manipulating Cell Fates with Protein Conjugates
    Yiao Wang, Carston R. Wagner, Mark Dewey Distefano · 2022 · Bioconjugate Chemistry
  31. mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation
    Xiaoqi Xue, Chen Zhang, Xiaolin Li, Junqiao Wang, Haowei Zhang, Ying Feng, Naihan Xu, Hongyan Li, Chunyan Tan, Yuyang Jiang et al. · 2024 · MedComm
  32. Metabolite-protein interactions: Native mass spectrometry and collision induced affinity selection mass spectrometry in natural product screening
    Yushu Gu, Miaomiao Liu, Ronald J. Quinn · 2022 · Frontiers in Analytical Science
  33. Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
    Can Zhao, Henian Wang, Wenhu Zhan, Xiaoqing Lv, Xiaodong Ma · 2023 · Journal of Medicinal Chemistry
  34. Small Molecule–Degrader Conjugates: Evaluating the Structure–Activity Relationship of Linkers to Overcome In Vivo Barriers in PROTAC Delivery
    Shiwei Song, Weina Jing, Lei Peng, Jiaqi Liu, Wanyi Tai · 2025 · Journal of Medicinal Chemistry
  35. Opportunities in proximity modulation: Bridging academia and industry
    Ivan Đikić, Cristina Mayor‐Ruiz, Georg E. Winter, Kerstin Koch, Alessio Ciulli, Nicolas H. Thomä · 2025 · Molecular Cell
  36. Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
    Anthony Cheung, Yi Liu, Alicia M. Chenoweth, Hanieh Montaseri, Benjamina Esapa, Vijay Chudasama, James R. Baker, David E. Thurston, Sophia N. Karagiannis · 2026 · Physiological Reviews
  37. Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
    Xinrui Yang, Yin He, Richard D. Kim, Jason B. Fleming, Hao Xie · 2020 · Targeted Oncology
  38. A Novel Synthetic Lethal Approach to Target MYC-Driven Cancers
    Roman M. Chabanon, Sophie C. Postel-Vinay · 2022 · Cancer Research
  39. Design, Synthesis, and Evaluation of Carbonate-Linked Halogenated Phenazine-Quinone Prodrugs with Improved Water-Solubility and Potent Antibacterial Profiles
    Tao Xiao, Ke Liu, Qiwen Gao, Man‐Yun Chen, Young S. Kim, Shouguang Jin, Yousong Ding, Robert W. Huigens · 2023 · ACS Infectious Diseases
  40. PROTAC Degraders
    Alessio Ciulli, Oliver Hsia · 2022
  41. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives
    Makenzie Vorderbruggen, Carlos A. Velázquez‐Martínez, Amarnath Natarajan, Adam R. Karpf · 2024 · International Journal of Molecular Sciences
  42. Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs
    Si-Han Zhang, Na Zeng, Jin‐Zhou Xu, Chen‐Qian Liu, Mengyao Xu, Jian‐Xuan Sun, Ye An, Xing‐Yu Zhong, Lin-Tao Miao, Shaogang Wang et al. · 2024 · Biomedicine & Pharmacotherapy
  43. Major Advances in Emerging Degrader Technologies
    Hang Luo, Li Wu, Yujian He, Chong Qin, Xinjing Tang · 2022 · Frontiers in Cell and Developmental Biology
  44. Design and Applications of Bifunctional Small Molecules in Biology
    Shelton R. Boyd, Lyra Chang, Wanderson Cabral de Rezende, Idris O. Raji, Prasanna Kandel, Secondra L. Holmes, Damian W. Young · 2020 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
  45. Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy
    Meiyang Xi, Fengxia Zhang, Jingjing Zhu, Hualiang Shen, Chunlei Wu, Xiaozhong Gao, Yonghua Wu, Yonghua Wu, Runpu Shen, Gang Xia · 2025 · European Journal of Medicinal Chemistry
  46. Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders
    Charlotte Crowe, Alessio Ciulli · 2026 · Chemical Reviews
  47. Welding PROxAb Shuttles: A Modular Approach for Generating Bispecific Antibodies via Site-Specific Protein–Protein Conjugation
    Tanja Lehmann, Hendrik Schneider, Jason Tonillo, Jennifer Schanz, Daniel F. Schwarz, Christian J. Schröter, Sebastian Jäger, Harald Kolmar, Stefan Hecht, Jan Anderl et al. · 2024 · Bioconjugate Chemistry
  48. Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology
    Irene Sevilla-Carrillo, Eloína García-Tercero, Carlos Alonso‐Moreno, Carmen Moya‐López · 2025 · Anti-Cancer Agents in Medicinal Chemistry
  49. HADDOCK-Guided modeling and molecular simulations of cereblon-based ternary complexes: Development of novel PROTACs for Ataxia telangiectasia and RAD3-Related (ATR) kinase
    Anne‐Christin Sarnow, Husam Nassar, Abdallah M. Alfayomy, Dina Robaa, Wolfgang Sippl · 2025 · Computers in Biology and Medicine
  50. Chemotherapeutic Drug—Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions
    Abhishek K. Tiwatane, Prakash Y. Khandave, Sampada Sharad Kulkarni, Kounosuke Oisaki, Abhay H. Pande · 2025 · Current Oncology Reports
  51. Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin
    Lin Zhang, Ling Li, Xia Wang, Huimin Liu, Yibin Zhang, Tiantian Xie, Hui Zhang, Xiaodong Li, Tianhuan Peng, Xing Sun et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  52. PROxAb Shuttle: A non-covalent plug-and-play platform for the rapid generation of tumor-targeting antibody-PROTAC conjugates
    Hendrik Schneider, Sebastian Jäger, Doreen Könning, Nicolas Rasche, Christian J. Schröter, Desislava Elter, Andreas Evers, Marc Lecomte, Federico Riccardi Sirtori, Daniel F. Schwarz et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  53. Expanding the druggable proteome strategies and innovations in targeted protein degradation
    Ke Ma, Ting Liu, Wen-Bo Huan, Ke-Zheng Chen, Sheng‐Lin Qiao · 2025 · Nano Today
  54. Current advances in the proteolysis-targeting chimeras (PROTACs) delivery systems
    Zhanzhan Feng, Shuyan Zhou, Xiao Li, Guoquan Wan, Kaiyan Xu, Zhiyong Qian · 2025 · Chinese Chemical Letters
  55. PROTAC-powered synergistic tumor therapy
    Xiaoyu Wang, Jingwen Zou, Yixuan Tao, Zhiwen Zhou, Changyu Bian, Zhiqiang Mao, Zhihong Liu · 2026 · TrAC Trends in Analytical Chemistry
  56. PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
    Mao Du, Tao Liu, Wenyu Wang, Shuai Fan, Mei Tian, Qing Du, Zhidong Wang, Xiaodong Li, Xiaoyu Liu, Qin Xia et al. · 2026 · European Journal of Medicinal Chemistry Reports
  57. Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
    Nikola Knoll, Nouri Neamati, Aykut Üren · 2026 · ACS Pharmacology & Translational Science
  58. Bacteria-Induced Oligopeptide Assembly Enables Effective Bacterial Killing with Low Cytotoxicity and Hemolysis
    Y. H. Cheng, He Zhao, Jiayi Sun, Shuaishuai Nie, Wen Li · 2025 · Biomacromolecules
  59. Next-generation drug conjugates for breast cancer: Clinical prospects and mechanism-based strategies to overcome resistance
    Monong Zhao, Wenjing Liu, Wenjia Lu, Zhiyu Li, Hongxi Wu · 2026 · Drug Discovery Today
  60. Targeted degradation of BRD4 by PROTACs: advances in cancer therapy
    Yanyun Hong, Xiang Liu, Yanfang Li, Mengting Yu, Caolin Wang, Cunpeng Nie, Shan Xu · 2026 · Chemical Communications
  61. From undruggable to degradable: Strategic expansion of targeted protein degradation in cancer therapy
    Jiyoon Sung, Yuna Seo, Jae-Young Lee · 2026 · Molecular Therapy
  62. Anti-tumor efficacy and Vδ2 T-cell activation via EGFR antibody-drug conjugates featuring novel aminobisphosphonates
    Doretta Cuffaro, Linda Di Gregorio, Camilla Mangini, Martina Taglieri, Serena Matis, Roberto Benelli, Massimo Ardy, Laura Salvini, Armando Rossello, Alessandro Delli Poggi et al. · 2025 · Scientific Reports
  63. Molecular glue degraders: Rational design, specificity engineering, and advanced delivery
    Lieen Ma, Ning Wang, Jingjing Zhu, Lingjie Wu, Shan He, Bin Zhang · 2026 · Acta Pharmaceutica Sinica B
  64. The HSP90-dependent bioorthogonal PROTAC prodrug system enables tumor-selective and enhanced protein degradation
    Fangkui Yin, Ting Song, Yang Song, Ke Wang, Hong Zhang, Maojun Jiang, Zihan Wang, Xiuwen Fan, Yanxin Zhang, Siyao Wang et al. · 2026 · Journal of Controlled Release
  65. Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
    Tingting Yao, Zheng Zhou, Guangji Wang, Zhe-ying Zhu, Xi-Nuo Li · 2026 · Acta Pharmacologica Sinica
  66. Native mass spectrometry for proximity-inducing compounds: a new opportunity for studying chemical-induced protein modulation
    Emanuele Fabbrizi, Francesco Fiorentino, Fabrizio Casano, Antonello Mai, Dante Rotili · 2025 · Expert Opinion on Drug Discovery
  67. In Silico-Driven THIOMAB Approach for Stable PROTAC Conjugates by Docking Payloads in Antibody Cavities
    Shiwei Song, Yahui Liu, Jiaqi Liu, Wanyi Tai · 2025 · Bioconjugate Chemistry
  68. Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
    Liuzhi Hu, Shuang Wu, Wentao Wang, Hongbo He, Jinxin Che, Mingfei Wu, Xiaowu Dong · 2025 · European Journal of Medicinal Chemistry
  69. Pharmacokinetic modeling to optimize development and therapeutic potential of mAb-based therapies
    Xiaoqing Fan, Chengcong Chen, Lin Zhang, Kangna Cao, Xiaoyu Yan · 2026 · Advanced Drug Delivery Reviews
  70. Targeted protein degradation: bridging chemical biology and clinical translation
    Yubo Zhang, Jun-wei Fu, Yue Liu, R Y Wu, Yanting Liang, Wei Zhang, Tao Yuan, Hao Zhu, Qiao-Jun He, Bo Yang · 2026 · Acta Pharmacologica Sinica
  71. Protein Ligases: Nature’s Gift for Protein/Peptide Synthesis
    Yvonne Ritsema, Huapeng Li, Qingfei Zheng · 2025 · BioChem
  72. Chemical control of multidomain acetyltransferase activity
    Whitney K. Lieberman, Yihang Jing, Jordan L. Meier · 2021 · Cell chemical biology
  73. Ternary Complex‐Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo‐PROTACs
    Claudia J. Diehl, Alessandra Salerno, Alessio Ciulli · 2024 · Angewandte Chemie
  74. Advancing proteolysis targeting chimeras toward clinical drug developments
    Xinjian Tian, Chaoqun Huang, Lin Yin, Xufen Yu · 2024 · Elsevier eBooks
  75. A mechanistic pharmacokinetic-pharmacodynamic model for degrader-antibody conjugates
    Martha P. Balthasar, Derek W. Bartlett · 2026 · Journal of Pharmacokinetics and Pharmacodynamics
  76. Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer
    Manuel Olazábal-Morán, C. Blázquez-Barbadillo, E. Pérez-Izquierdo, M. Muñoz-Silva, A. Garrido · 2026 · Advanced Drug Delivery Reviews
  77. PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
    Sunny Periyasamy, Thyla Jarrett, Joe Truong, Rachid Skouta · 2026 · Journal of Enzyme Inhibition and Medicinal Chemistry
  78. Research progress and future perspectives in proteolysis-targeting chimeras
    Nuofan Wu, Zihui Xu, Shuhong Dai, Qianqian Wang · 2026 · Frontiers in Pharmacology
  79. Active targeting strategies for PROTAC delivery in cancer therapy: Advances, challenges, and future perspectives
    Meihan Liu, Yaoshu Song, Kexin Luo, Yongsheng Zhao, Hongpan Zhang · 2026 · Critical Reviews in Oncology/Hematology
  80. The role of ubiquitin system in ageing-related diseases and potential therapeutic opportunities
    Xiaoya Ren, Xin Zhou, Zhiqiang Ma, Liu D · 2026 · Molecular Biomedicine
  81. Harnessing multispecific antibodies for next-generation cancer treatments
    Wen-Qian Liu, Zheng Xiao-li, Xing‐Xing Fan · 2026 · Pharmacology & Therapeutics
  82. COMPASS: A Computational Pipeline to Identify Linkers Predicting Ubiquitinable PROTAC‐Induced Ternary Complexes
    Sébastien Sueron, Sayyed Jalil Mahdizadeh, Éric Chevet, X. Guillory, François‐Hugues Porée, Leif Axel Eriksson · 2026 · ChemMedChem
  83. Recent advances in antibody–drug conjugates
    Jack D. Sydenham, Thomas Wharton, David R. Spring · 2026 · Current Opinion in Chemical Biology
  84. Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives
    Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li · 2026 · MedComm
  85. The ADC-driven development paradigm and evolution into XDC: Current landscape and future trends
    Li Lin, Chengyi Zuo, Linling Zhou, Zhaorui Chen, Yinli Xia, Zhanghong Kong, Menghui Qi, Mengxian Niu, Yuhan Hou, Hai Han et al. · 2026 · Acta Pharmaceutica Sinica B
  86. PROTACs in Treatment of Glioma
    Sachin Kumar, Vikas Maharshi · 2024 · Springer eBooks
  87. Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
    Anna Shemorry, Willem den Besten, Melinda M. Mulvihill, Curt J. Essenburg, Nicole Blaquière, Tracy Kleinheinz, Elisia Villemure, Frank Peale, Gauri S. Deshmukh, Danilo Maddalo et al. · 2025 · Cell chemical biology
  88. A viral infection-biomimetic strategy for antibody-guided targeted protein degradation
    Yuanyuan Yang, Chuanda Zhu, Xiaojun Wang, Lidong Gong, Qiang Ma, Yujie Luo, Hongjun Wang, Dan Lu, Ridong Li, Qiang Zhang et al. · 2025 · Acta Biomaterialia
  89. Structural and Biophysical Principles of Degrader Ternary Complexes
    David Zollman, Alessio Ciulli · 2020 · Royal Society of Chemistry eBooks
  90. Faculty Opinions recommendation of Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
    Cheng‐Ming Chiang · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  91. Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery
    Paola Martinelli, Christiane C. Kofink, Georg Boeck, Harald Weinstabl, Manfred Koegl · 2022 · Wiley eBooks
  92. Drug Properties
    Siamak Cyrus Khojasteh, Harvey Wong, Donglu Zhang, Cornelis E. C. A. Hop · 2022 · Springer eBooks
  93. Intrazellulärer Transport nativer Proteine durch Bioreversible Arginin‐Modifikation (BioRAM) primärer Aminogruppen
    Jonathan Franke, Jan Vincent V. Arafiles, Christian Leis, Christian P. R. Hackenberger · 2025 · Angewandte Chemie
  94. Protease-mediated degradation
    Lu Yang, Haiting Duan, Xinfei Mao, Bizhi Li, Jinxin Che, Xiaowu Dong · 2025 · Elsevier eBooks
  95. Novel Antibody Technologies
    Fay Lin · 2026 · Genetic Engineering & Biotechnology News
  96. DNA‐Encoded Libraries for the Discovery of E3 Ligase Ligands
    Lulu Wen, Qingqing Zhang, Zhiqiang Duan, Rui Jin, Xiaojie Lu · 2026 · ChemMedChem
  97. Targeted protein degradation in inflammatory bone diseases: Mechanistic basis and therapeutic opportunities
    Yu-Xuan Wu, Yuan-Hao Wen, Qiu-Hui Li, Lu Zhang · 2026 · Translational research
  98. A bulk cell heterozygous knock-in strategy for targeted protein degradation
    Beibei Liu, Chao Qi, Tomoharu Kanie · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  99. BindingDB Entry 50015880: Estimating the cooperativity of PROTAC-induced ternary complexes using
    BindingDB · 2023 · Discovery Research Portal (University of Dundee)
  100. Targeted protein degradation: mechanistic diversity, therapeutic expansion, and clinical translation
    Caiyu Wang, Zhibin Guo, Yufei Liu, Qichao Gao, Qing Wang, Yi Liu, Yujiao Liu · 2026 · International Journal of Pharmaceutics